{"id":198995,"name":"EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC )","slug":"emergent-biosolutions-inc-fka-adapt-pharma-inc","state":"PA","country":"United States of America","description":"Cutting-edge treatments for patients with special medical conditions","totalSpending":130000,"filings":8,"yearlySpending":[{"year":2018,"income":90000},{"year":2019,"income":40000}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["BURRELL INTERNATIONAL GROUP LLC"],"lobbyists":["DEBORAH BURRELL"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Opioid and heroin addiction legislation, Naloxone access.","House and Senate Opioid Packages:  \nH.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act;\nS.3120 - 115th Congress (2017-2018) HEAL Act of 2018;\nH.R.5925 - 115th Congress (2017-2","HR 6, Labor HHS Appropriations;\nCARA 2.0;\nPOWER Act; \nNaloxone access provisions, generally;\nOpioid Package, issues relating to:  naloxone access, coprescribing/opioid prescribing guidelines,\nJudiciar","HR 6, Labor HHS Appropriations;\nCARA 2.0;\nPOWER Act; \nNaloxone access provisions, generally;\nOpioid Package, issues relating to:  naloxone access, coprescribing/opioid prescribing guidelines,\nJudiciar","NDAA - provisions related to biological and chemical defense\nOpioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines"]}